Abstract:Hypoxia-inducible factor 1 (HIF-1) is the central mediator of cellular responses to low oxygen and has recently become an important therapeutic target for solid tumor therapy. Inhibition of HIF-1 is expected to result in the attenuation of hypoxia-inducible genes, which are vital to many aspects of tumor biology, including adaptative responses for survival under anaerobic conditions. To identify small molecules inhibiting the HIF-1 pathway, we did a biological screen on a 10,000-membered natural product-like combinatorial library. The compounds of the library, which share a 2,2-dimethylbenzopyran structural motif, were tested for their ability to inhibit the hypoxic activation of an alkaline phosphatase reporter gene under the control of hypoxia-responsive elements in human glioma cells. This effort led to the discovery of 103D5R, a novel small-molecule inhibitor of HIF-1α. 103D5R markedly decreased HIF-1α protein levels induced by hypoxia or cobaltous ions in a dose- and time-dependent manner, whereas minimally affecting global cellular protein expression levels, including that of control proteins such as HIF-1β, IκBα, and β-actin. The inhibitory activity of 103D5R against HIF-1α was clearly shown under normoxia and hypoxia in cells derived from different cancer types, including glioma, prostate, and breast cancers. This inhibition prevented the activation of HIF-1 target genes under hypoxia such as vascular endothelial growth factor (VEGF) and glucose transporter-1 (Glut-1). Investigations into the molecular mechanism showed that 103D5R strongly reduced HIF-1α protein synthesis, whereas HIF-1α mRNA levels and HIF-1α degradation were not affected. 103D5R inhibited the phosphorylation of Akt, Erk1/2, and stress-activated protein kinase/c-jun-NH2-kinase, without changing the total levels of these proteins. Further studies on the mechanism of action of 103D5R will likely provide new insights into its validity/applicability for the pharmacologic targeting of HIF-1α for therapeutic purposes.

Inhibition of Hypoxia-Inducible Transcription Factor (Hif-1Α) Signaling with Sulfonyl-γ-AApeptide Helices.

Potent Inhibition of HIF1α and p300 Interaction by a Constrained Peptide Derived from CITED2

Α-Helix-mimicking Sulfono-γ-AApeptide Inhibitors for P53–mdm2/mdmx Protein–Protein Interactions

Helical Sulfonyl-γ-AApeptides in the Inhibition of HIV-1 Fusion and HIF-1α Signaling

Identification of small molecule compounds that inhibit the HIF-1 signaling pathway

Design, synthesis, and hypoxia-inducible factor-1α inhibitory activity evaluation of panaxadiol derivatives containing a thiazole moiety

Synthesis and evaluation of 3-(phenylethynyl)-1,1′-biphenyl-2-carboxylate derivatives as new HIF-1 inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Engineered coiled-coil HIF1α protein domain mimic

Design on a Rational Basis of High-Affinity Peptides Inhibiting the Histone Chaperone ASF1

Identification of a Novel Small-Molecule Inhibitor of the Hypoxia-Inducible Factor 1 Pathway

Design and Evaluation of Α-Helix-based Peptide Inhibitors for Blocking PD-1/PD-L1 Interaction.

An efficient strategy for digging protein-protein interactions for rational drug design - A case study with HIF-1α/VHL

Inhibition of the HSP90 homodimerization and HSP90-HIF1α interactions by employing small molecules at C-terminal ATP binding site of HSP90

Sulfonyl γ-AApeptide tools for modulating biology

Design and Synthetic Strategies for Helical Peptides.

Rational Design of Sulfonyl-?-AApeptides as Highly Potent HIV-1 Fusion Inhibitors with Broad-Spectrum Activity

Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions

Benzo[d]isoxazole Derivatives As Hypoxia-Inducible Factor (Hif)-1Α Inhibitors

Structure-guided optimisation of N -hydroxythiazole-derived inhibitors of factor inhibiting hypoxia-inducible factor-α

Novel X-linked Inhibitor of Apoptosis Protein Inhibitors As Probes of Apoptosis in Biology and Medicine